# AN2 Therapeutics, Inc.: overview ANTX · Nasdaq · CIK 1880438 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/antx.md) · [Financials](/companies/antx/financials.md) · [Filings](/companies/antx/filings.md) · [Insiders](/companies/antx/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.43)](/filings/0001193125-25-277673.md) | not reported | [(0.35)](/filings/0001193125-26-216755.md) | [(0.21)](/filings/0001193125-26-344569.md) | [(0.31)](/filings/0001193125-25-277673.md) | not reported | [(0.29)](/filings/0001193125-26-216755.md) | [(0.18)](/filings/0001193125-26-344569.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(10.64)](/filings/0000950170-23-010627.md) | [(2.79)](/filings/0000950170-24-038681.md) | [(2.74)](/filings/0000950170-25-044366.md) | [(1.72)](/filings/0001193125-26-110693.md) | [(1.16)](/filings/0001193125-26-110693.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/antx/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Vivo Capital, LLC](/funds/1674712.md) | 2026-06-30 | $15.3m | 3,153,640 | | Unchanged | | [Commodore Capital LP](/funds/1831942.md) | 2026-06-30 | $14.2m | 2,933,680 | | Added +599,967 | | [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $11.2m | 2,318,692 | | Added +96,190 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $8.1m | 1,665,494 | | Added +1,346,726 | | [Spruce Street Capital LP](/funds/2050194.md) | 2026-06-30 | $8.0m | 1,661,073 | | Unchanged | | [Almitas Capital LLC](/funds/1596468.md) | 2026-06-30 | $7.1m | 1,469,129 | | Reduced −10,000 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $6.0m | 1,238,705 | | Added +227,627 | | [ADAGE CAPITAL PARTNERS GP, L.L.C.](/funds/1165408.md) | 2026-06-30 | $4.8m | 1,000,000 | | Unchanged | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $4.6m | 951,997 | | Added +796,758 | | [Boxer Capital Management, LLC](/funds/2018299.md) | 2026-06-30 | $3.6m | 749,035 | | Unchanged | ## Recent filings [All 382 filings](/companies/antx/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-11 | 20:04 ET | [10-Q](/filings/0001193125-26-344569.md) | Quarterly report, period 2026-06-30 | 0001193125-26-344569 | | 2026-08-11 | 20:01 ET | [8-K](/filings/0001193125-26-344549.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-344549 | | 2026-06-09 | 22:23 ET | [8-K](/filings/0001193125-26-262264.md) | 5.07 Shareholder vote results | 0001193125-26-262264 | | 2026-06-04 | 20:15 ET | [8-K](/filings/0001193125-26-257430.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-257430 | | 2026-05-11 | 20:08 ET | [10-Q](/filings/0001193125-26-216755.md) | Quarterly report, period 2026-03-31 | 0001193125-26-216755 | | 2026-05-11 | 20:06 ET | [8-K](/filings/0001193125-26-216752.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-216752 | | 2026-04-22 | 20:01 ET | [DEF 14A](/filings/0001193125-26-170314.md) | Proxy statement, period 2026-04-22 | 0001193125-26-170314 | | 2026-04-09 | 21:03 ET | [8-K](/filings/0001193125-26-149822.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-149822 | | 2026-03-20 | 20:37 ET | [8-K](/filings/0001193125-26-117765.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-117765 | | 2026-03-17 | 20:03 ET | [10-K](/filings/0001193125-26-110693.md) | Annual report, period 2025-12-31 | 0001193125-26-110693 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-110693.md), filed Mar 17, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1880438 - Tickers: ANTX - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.